Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company Mar 4, 2020 04:03PM
Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures Feb 13, 2020 04:02PM
Antibiotics maker Melinta files for Chapter 11 bankruptcy Dec 27, 2019 10:56AM
Melinta Therapeutics (MLNT) initiates voluntary proceedings under Chapter 11 of U.S. Bankruptcy Code Dec 27, 2019 09:04AM
Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility Dec 27, 2019 09:02AM


Dec 27, 2019 09:02AM Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility
Nov 12, 2019 05:07PM Melinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2019
Nov 12, 2019 05:07PM Melinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2019
Oct 24, 2019 04:48PM Melinta Therapeutics (MLNT) Reports FDA Approval of Supplemental NDA for BAXDELA (delafloxacin) for Treatment of CABP
Oct 24, 2019 04:02PM Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Oct 24, 2019 04:02PM Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Sep 3, 2019 04:13PM Melinta Therapeutics (MLNT) Announces Appointment of Jennifer Sanfilippo to Interim CEO and Director
Sep 3, 2019 04:05PM Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director
Sep 3, 2019 04:05PM Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director